Overview

CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the efficacy and safety of Bemiparin, a second-generation LMWH, in the prophylaxis of VTE (using a postoperative regimen, i.e. administering the first dose 6 hours after finishing the surgical procedure) for 28 days compared to 8 days, in oncological surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Rovi Pharmaceuticals Laboratories
Treatments:
Bemiparin
Heparin, Low-Molecular-Weight